Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Double bronchodilator versus triple inhaled therapy versus conventional treatment in bronchiectasis with COPD
ChiCTR2200058796Phase 4Not yet recruiting
- Sponsor
- Jinan Eighth People's Hospital
- Start
- Apr 2022
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of glycopyrronium, formoterol and budesonide in bronchiectasis and chronic obstructive pulmonary disease (COPD) (3 arms), sponsored by Jinan Eighth People's Hospital. Primary endpoints: T lymphocyte subsets, Chest CT determination and 3 more. Planned start Apr 2022; status: not yet recruiting.
02
Drugs
glycopyrroniumformoterolbudesonide
03
Conditions
bronchiectasischronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on ChiCTR2200058796.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200058796.